Evelyn Ling, M.D., M.S. is a Clinical Instructor at Stanford School of Medicine. She completed her M.D. degree and her internal medicine residency at the University of California at Davis in 2017. Prior to her medical training, she received her B.S. in biomedical computation and M.S. in Management Science and Engineering from Stanford University. In medical school and residency, she worked on projects in quality improvement (medication reconciliation in the hospital setting), medical education (clinical reasoning development) and health care technology (remote diabetes management). At ValleyCare, she has continues to be involved in medical education as the site co-director for Practice of Medicine course (POM) for second year physician assistant students as well as quality improvement projects in ED admissions and wellness. She is a Bay Area native and is excited to be working with the East Bay community.

Clinical Focus

  • Internal Medicine
  • Hospital Medicine

Academic Appointments

  • Clinical Assistant Professor, Medicine

Administrative Appointments

  • Site Co-Director, Practice of Medicine Y2; Practicum (2018 - Present)

Boards, Advisory Committees, Professional Organizations

  • Member, SHC-VC Strategy for Research & Education Work Group (2019 - Present)
  • Physician Co-Champion, SHC-VC Research Committee (2019 - Present)

Professional Education

  • Medical Education: University of California Davis School of Medicine (2014) CA
  • Board Certification: American Board of Internal Medicine, Internal Medicine (2017)
  • Residency: UC Davis Internal Medicine Residency (2017) CA

Clinical Trials

  • Adaptive COVID-19 Treatment Trial (ACTT) Recruiting

    This study is an adaptive, randomized, double-blind, placebo-controlled trial to evaluate the safety and efficacy of novel therapeutic agents in hospitalized adults diagnosed with COVID-19. The study is a multicenter trial that will be conducted in up to approximately 100 sites globally. The study will compare different investigational therapeutic agents to a control arm. There will be interim monitoring to introduce new arms and allow early stopping for futility, efficacy, or safety. If one therapy proves to be efficacious, then this treatment may become the control arm for comparison(s) with new experimental treatment(s). Any such change would be accompanied by an updated sample size. Because background standards of supportive care may evolve/improve over time as more is learned about successful management of COVID-19, comparisons of safety and efficacy will be based on data from concurrently randomized subjects. An independent Data and Safety Monitoring Board (DSMB) will actively monitor interim data to make recommendations about early study closure or changes to study arms. To evaluate the clinical efficacy, as assessed by time to recovery, of different investigational therapeutics as compared to the control arm.

    View full details

All Publications

  • From Paper to EHR: A Millennial's Perspective Ling, E., Cha, A., Ahuja, N. Medscape. Medscape Hospital Medicine. 2019 ; Perspective
  • Man's best friend, fatal in the end. Cleveland Clinic journal of medicine Ling, E., Howell, S., Vang, M., Aronowitz, P. 2017; 84 (2): 146–50

    View details for DOI 10.3949/ccjm.84a.16061

    View details for PubMedID 28198689

  • Too Fast for Comfort: Tachycardia in Postablation Wolff-Parkinson-White. The American journal of medicine Ling, E. B., Stayton, T. L., Stripe, B. R., Srivatsa, U., Amsterdam, E. A., Venugopal, S. 2016; 129 (11): e269–e272

    View details for DOI 10.1016/j.amjmed.2016.05.026

    View details for PubMedID 27296330

  • Mice lacking the beta 2 adrenergic receptor have a unique genetic profile before and after focal brain ischaemia ASN NEURO White, R. E., Palm, C., Xu, L., Ling, E., Ginsburg, M., Daigle, B. J., Han, R., Patterson, A., Altman, R. B., Giffard, R. G. 2012; 4 (5): 343-356

    View details for DOI 10.1042/AN20110020

    View details for Web of Science ID 000308887200005